In a nutshell This study investigated if concurrent (cCRT) or sequential chemoradiotherapy (sCRT) was more effective in non-small cell lung cancer (NSCLC). They found that sCRT was associated with better survival than cCRT. Some background Non-small cell lung cancer (NSCLC) is a common cancer. It is usually diagnosed at an advanced stage. Standard...
Read More
In a nutshell This study wanted to find out how well stereotactic body radiotherapy (SBRT) works in patients with non-small cell lung cancer (NSCLC) that has spread to one or two parts of the body (oligometastatic). The study found that SBRT is a good treatment option for these patients. Some background Stereotactic body radiotherapy (SBRT)...
Read MoreIn a nutshell This study is searching for participants with advanced solid tumors to try a new treatment called repotrectinib (TPX-0005). The main outcomes that will be measured include side effects, the most effective dose and response. This trial is recruiting in the United States and Korea. The details Patients with different genetic mutations...
Read More
In a nutshell This trial is examining the effectiveness and toxicity of COTI-2 treatment in patients with advanced cancer. The main outcomes to be measured will be cancer response to the treatment and number of side effects. This study is being conducted in Texas, US. The details Cancer resistance to therapy affects successful cancer treatment. The...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced solid tumors. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details The treatment options for advanced cancer are limited. New drugs are...
Read MoreIn a nutshell This phase 1/2 trial will investigate the safety of ALKS 4230 (ALKS) in advanced solid tumors. The main outcome will be adverse events and toxicities and disease control. This trial is recruiting at multiple locations in the US and Canada. The details The treatment options for advanced cancer are limited. New drugs are...
Read MoreIn a nutshell This phase 2 trial will investigate the effect of vopratelimab (JTX-2011) and ipilimumab (Yervoy) in non-small cell lung cancer (NSCLC). The main outcome will be the overall response (OR). This trial is recruiting at multiple locations in the US. The details Non-small cell lung cancer (NSCLC) is the most...
Read MoreIn a nutshell This trial aims to investigate the safety and effectiveness of durvalumab (Imfinzi) combined with chemotherapy and radiation in patients with advanced lung tumors. The main outcome that will be measured is if there are any side effects and survival without signs of disease. The details Duravalumab is an anti-cancer...
Read More
In a nutshell This study investigated female fertility preservation (FFP) in cancer patients. They found that FFP should be discussed with all women of reproductive age undergoing cancer treatment. Some background Cancer can have many negative effects on patient health. Infertility is a particular concern for younger female patients. Pregnancy rates...
Read More
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to address this. Immune...
Read MoreIn a nutshell This study reviewed the use of immunotherapy in non-small cell lung cancer (NSCLC). Some background Immunotherapy is a relatively new treatment strategy for cancer. It is particularly important in non-small cell lung cancer (NSCLC). Many patients with NSCLC are diagnosed at an advanced stage. One promising immunotherapy is...
Read More
In a nutshell This study investigated if durvalumab (Infinzi) is effective in advanced non-small cell lung cancer (NSCLC) that has progressed on previous therapies. They found that the response to durvalumab was greatest in patients with high PD-L1 expression. Some background Non-small cell lung cancer (NSCLC) is the most common form...
Read More
